Share: Facebook Twitter LinkedIn
Activity Provided By:

American Academy of CME

The Use of Direct Acting Oral Anti-Coagulants in Vulnerable Populations

Access Activity

Overview / Abstract:

Recommendations and evidence surrounding the use of DOAC’s in special populations continue to evolve to address concerns of use in patients with obesity, renal disease, active malignancy, and older adults. DOAC’s are a widely prescribed newer class of medications with emerging clinical recommendations and evidence for safe use. Pharmacists have a key role to play as part of the care team in formulating anticoagulation regimens that are appropriate for individual patients, and would benefit from education on the efficacy and safety of DOAC’s in vulnerable populations.


Sep 30, 2022


Pharmacy CPE



Credits / Hours




Presenters / Authors / Faculty

Maya R. Chilbert (Holsen), PharmD, BCCP
Clinical Assistant Professor
University at Buffalo School of Pharmacy and Pharmaceutical Sciences

Activity Specialities / Related Topics

Cardiology / Cardiovascular, Hematology, Oncology / Cancer / Radiation Therapy, Pharmacology

Sponsors / Supporters / Grant Providers

Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Keywords / Search Terms

American Academy of CME Oral Anti-Coagulants Vulnerable populations Medically ill direct acting oral anti-coagulants (DOAC’s) Pharmacy atrial fibrillation anticoagulation regimen Venous thromboembolism (VTE) Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map